Solid TumorPhase 1DOPNP201NCT02274610
Pharmacokinetic Study of Docetaxel-PNP and Taxotere to Treat Patient With Advanced Solid Cancer
A Phase 1 study testing Docetaxel-PNP and Taxotere in people with Solid Tumor, run by Samyang Biopharmaceuticals Corporation.
Trial summary
Evaluation of the pharmacokinetic equivalence of two Docetaxel formulations in terms of AUC and Cmax Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Solid Tumor
- What is being tested?
- Docetaxel-PNP and Taxotere
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 18 participants
- Where
- No sites listed yet
- Study dates
- Nov 2014to Dec 2015
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patient ages more than 18 years old
- Patient should voluntarily sign a written informed consent before study entry
- Patient historically or cytologically confirmed diagnosis of advanced solid tumor and patient with measurable disease or evaluable disease by RECIST criteria
- Progressive disease with development of new lesions or an increase in preexisting lesions or standard therapy in order to provide clinical benefit does not exist or is no longer effective
- Previous anti-cancer therapies must be completed before 21days of first study dose and Patient must have recovered from any previous therapy
- Patient has an Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
Show all 15Show fewer
- Patient has a life expectancy of at least 3 months
- Baseline studies for determining eligibility must be completed within 14 days of first study dose and patient has a adequate organ function including the following:
- Hb ≥ 10g/dl
- ANC ≥ 1.5 X 109/L
- Platelet count ≥ 100 X 109/L
- Serum total bilirubin ≤ 1.5 mg/dL
- Serum AST and ALT ≤ 2.5 X UNL
- Serum ALP ≤ 2.5ⅹUNL
- Serum creatinine ≤ 1.5 X UNL
Who cannot join
- Patient has had a major surgery except tumor ablation within 2 weeks before screening visit
- Patient has a brain metastasis with neurologic symptom
- Patient has a sensory neuropathy or motor neuropathy ≥ grade 2 by NCI-CTCAE
- Patient has any serious concurrent disease such as:
- Any medical or psychiatric condition that, in the opinion of the investigator, would prohibit the understanding and giving of informed consent Severe cardiovascular disease (e.g. ischemic heart disease requiring medication or myocardial infraction within the past six months, grade 3-4 congestive heart failure defined by the New York Heart Association criteria) Active un controlled infection.
- Patient has hypersensitivity to the Investigational product or their excipients
Show all 12Show fewer
- Patient has participated in any other clinical trial within 4 weeks before screening visit
- Woman is pregnant or breast feeding
- Subjects who are of childbearing potential who do not use a medically acceptable method of birth control or do not agree to continue use of this method throughout the trial (screening, treatment period, and 3 weeks from the last done). A negative pregnancy test (urine or serum) should be documented within 14 days prior to initiation of trial medication for women of childbearing potential who have not been amenorrheic for at least 12 months prior to registration into the trial or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy). Medically acceptable methods include:
- Barrier method with spermicide
- Intrauterine device
- Complete abstinence, etc.
About this study
Official title: Phase I Trial to Compare Pharmacokinetics and Safety of Docetaxel PNP With Taxotere in Subjects With Advanced Solid Tumor
Evaluation of the pharmacokinetic equivalence of two Docetaxel formulations in terms of AUC and Cmax
Read the detailed description
Comparison of pharmacokinetic parameters (T1/2β, CL, Vdss) Safety as measured by adverse events
- Conditions
- Solid Tumor
- Being tested
- Docetaxel-PNP, Taxotere
- Keywords
- docetaxel, Pharmacokinetic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Docetaxel-PNPDrug
Docetaxel Polymeric Nanoparticle Formulation
TaxotereDrug
Docetaxel
| Study group | Role | What they receive |
|---|---|---|
| Group A | Experimental | Period 1: Docetaxel-PNP / Washout: 3 weeks / Period 2: Taxotere Receives: Drug: Docetaxel-PNP; Drug: Taxotere |
| Group B | Experimental | Period 1: Taxotere / Washout: 3 weeks / Period 2: Docetaxel-PNP Receives: Drug: Docetaxel-PNP; Drug: Taxotere |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pharmacokinetics of DocetaxelPNP and Taxotere in terms of Area Under the Curve (AUC)
Measured: 3 months
Secondary outcomes (4)
Elimination Half Life (T1/2) of DocetaxelPNP and Taxotere
Measured: 3 months
Clearance (CL) of DocetaxelPNP and Taxotere
Measured: 3 months
Volume of Distribution at steady state (Vdss) of DocetaxelPNP and Taxotere
Measured: 3 months
Number of participants with Adverse Events
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Oct 2014 (estimated)
- Study startNov 2014
- Primary completionNov 2015
- Study completionDec 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Solid TumorStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 18 participants (actual)
Sponsor and investigators
- Lead sponsor
- Samyang Biopharmaceuticals Corporation
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Mi-ryung Jin, Masters, Study director, Samyang Biopharmaceuticals Corporation
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02274610
- Sponsor's protocol ID
- DOPNP201
- Acronym
- DOPNP201
- Status last verified
- Oct 2014
- First submitted
- 14 Oct 2014
- Last updated
- 1 May 2017
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 May 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Phase I Trial to Compare Pharmacokinetics and Safety of Docetaxel PNP With Taxotere in Subjects With Advanced Solid Tumor
- ClinicalTrials.gov ID
- NCT02274610
- Acronym / sponsor ID
- DOPNP201 / DOPNP201
- Conditions
- Solid Tumor
- Keywords
- docetaxel, Pharmacokinetic
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 18 participants (actual)
- Lead sponsor
- Samyang Biopharmaceuticals CorporationIndustry (pharma, biotech, devices)
- Study start
- Nov 2014 (actual)
- Primary completion
- Nov 2015 (actual)
- Study completion
- Dec 2015 (actual)
- First posted
- 24 Oct 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Evaluation of the pharmacokinetic equivalence of two Docetaxel formulations in terms of AUC and Cmax
Detailed description
Comparison of pharmacokinetic parameters (T1/2β, CL, Vdss) Safety as measured by adverse events
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group A | Experimental | Drug: Docetaxel-PNP, Drug: TaxoterePeriod 1: Docetaxel-PNP / Washout: 3 weeks / Period 2: Taxotere |
| Group B | Experimental | Drug: Docetaxel-PNP, Drug: TaxoterePeriod 1: Taxotere / Washout: 3 weeks / Period 2: Docetaxel-PNP |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (15 listed)
- Patient ages more than 18 years old
- Patient should voluntarily sign a written informed consent before study entry
- Patient historically or cytologically confirmed diagnosis of advanced solid tumor and patient with measurable disease or evaluable disease by RECIST criteria
- Progressive disease with development of new lesions or an increase in preexisting lesions or standard therapy in order to provide clinical benefit does not exist or is no longer effective
- Previous anti-cancer therapies must be completed before 21days of first study dose and Patient must have recovered from any previous therapy
Key exclusion criteria (12 listed)
- Patient has had a major surgery except tumor ablation within 2 weeks before screening visit
- Patient has a brain metastasis with neurologic symptom
- Patient has a sensory neuropathy or motor neuropathy ≥ grade 2 by NCI-CTCAE
- Patient has any serious concurrent disease such as:
- Any medical or psychiatric condition that, in the opinion of the investigator, would prohibit the understanding and giving of informed consent Severe cardiovascular disease (e.g. ischemic heart disease requiring medication or myocardial infraction within the past six months, grade 3-4 congestive heart failure defined by the New York Heart Association criteria) Active un controlled infection.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Docetaxel-PNPDocetaxel Polymeric Nanoparticle Formulation | Drug | Group A, Group B |
| TaxotereDocetaxel | Drug | Group A, Group B |
Primary outcome
Pharmacokinetics of DocetaxelPNP and Taxotere in terms of Area Under the Curve (AUC)
Time frame: 3 months
4 secondary outcomes
Elimination Half Life (T1/2) of DocetaxelPNP and Taxotere
Time frame: 3 months
Clearance (CL) of DocetaxelPNP and Taxotere
Time frame: 3 months
Volume of Distribution at steady state (Vdss) of DocetaxelPNP and Taxotere
Time frame: 3 months
Number of participants with Adverse Events
Time frame: 3 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 May 2017.
Related trials for Solid Tumor
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
Active, not recruitingPhase 1
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid Tumor
Neoplasms
Active, not recruitingPhase 3
A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial
Solid Tumors
RecruitingPhase 1
IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid Tumors
Relapsed Solid Tumor Malignancies, Refractory Solid Tumor Malignancies
RecruitingObservational study
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Malignant Solid Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mi-ryung Jin, Masters study director
Samyang Biopharmaceuticals Corporation
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Docetaxel-PNP and Taxotere in people with Solid Tumor, run by Samyang Biopharmaceuticals Corporation.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 15 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 May 2017. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pharmacokinetics of DocetaxelPNP and Taxotere in terms of Area Under the Curve (AUC) (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 May 2017.